G1 Therapeutics (GTHX) PT Raised to $41 at Raymond James, Following Discussion With Management Following Clinical Update
Tweet
Share
E-mailGet Alerts GTHX Hot Sheet
Price: $3.99 -4.77%
Rating Summary:
9 Buy, 0 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
9 Buy, 0 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Raymond James analyst Dane Leone raised the price target on G1 Therapeutics (NASDAQ: GTHX) to $41.00 (from $21.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Downgrades LTIMindtree Ltd (LTIM:IN) to Underperform
- Goldman Sachs Upgrades The TJX Companies (TJX) to Buy
- Bunzl Plc. (BNZL:LN) (BZLFY) PT Raised to GBP33 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Raymond JamesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
